Shares in Spectrum Pharmaceuticals Inc. have taken a battering on the news that the US firm's investigational lung cancer drug poziotinib failed to meet its main goal in a mid-stage clinical trial.
The Nevada-headquartered group reported that the primary endpoint in its Phase II trial called Zenith20 evaluating poziotinib in previously treated non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations was not met in the first group of 115 patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?